BioticsAI Founder on Medical AI: FDA Approval, Fundraising, and Real-World Challenges

Medical AI Startups: The Reality Behind the Hype

As AI technology sweeps across industries, healthcare is widely recognized as one of the most promising yet most difficult sectors to crack. Stringent regulatory approvals, lengthy product deployment cycles, and steep compliance costs deter countless entrepreneurs. Recently, BioticsAI CEO Robhy Bustami sat down with host Isabelle Johannessen on the tech podcast Build Mode for an in-depth conversation, candidly sharing his real-world experiences and insights from building a company in the medical AI space.

FDA Approval: A Long-Distance Endurance Race

During the interview, Bustami acknowledged that FDA approval is one of the biggest challenges facing medical AI companies. Unlike consumer-grade AI products that follow a "move fast and ship fast" cadence, medical AI products must undergo rigorous safety and efficacy validation before receiving regulatory clearance.

He noted that many AI entrepreneurs underestimate the complexity of the compliance process when entering the healthcare sector. From collecting and validating clinical data to engaging in extensive back-and-forth communications with FDA review teams, every step demands significant time and resources. BioticsAI's experience shows that planning a regulatory strategy early and incorporating compliance requirements into the initial product design phase are key to shortening the approval timeline.

"Many people think getting FDA approval is the finish line, but in reality, it's just the starting point," Bustami emphasized. Post-approval challenges such as market promotion, hospital procurement processes, and physician training are equally daunting.

The Funding Dilemma: Convincing Investors to Back a 'Slow Business'

Another major real-world challenge for medical AI lies in fundraising. Compared to AI applications that can scale rapidly and monetize quickly, medical AI companies typically require longer R&D cycles and greater upfront investment, demanding far more patience from investors.

Bustami shared BioticsAI's fundraising strategy: on one hand, the team needs to clearly demonstrate the product's clinical value and market potential to investors; on the other hand, they must honestly communicate the unique nature of the medical AI sector — this is not a field where fortunes are made overnight, but rather a marathon requiring long-term commitment.

He mentioned that in recent years, as the digital health sector has heated up, an increasing number of specialized healthcare-focused funds have emerged. These "industry-savvy" investors are better positioned to understand the pace and logic of medical AI and are more willing to give startup teams adequate room to grow.

Team Management: Staying Motivated Amid Regulatory Red Tape

One thought-provoking topic that arose during the interview was: How do you maintain team morale and creativity when so much time and energy is consumed by regulatory compliance?

Bustami believes the key is ensuring every team member understands the significance of the company's mission. The ultimate goal of medical AI is to improve patient health outcomes, and this sense of purpose can help teams stay motivated even when facing tedious red tape. He also stressed the importance of setting milestone-based goals — breaking down the lengthy approval process into measurable milestones so the team can draw a sense of accomplishment from each small victory.

Industry Outlook: The Golden Age of Medical AI Is Approaching

Despite the myriad challenges, Bustami remains highly optimistic about the future of medical AI. He believes that with continued advances in AI technology, the gradual maturation of regulatory frameworks, and the accelerating digital transformation of healthcare institutions, medical AI is entering an era of unprecedented opportunity.

From a global market perspective, the FDA has approved hundreds of AI/ML-enabled software as medical devices (SaMD) in recent years, and the approval process continues to be refined. Meanwhile, major markets such as China and the European Union are also fast-tracking the development of regulatory standards for AI medical products, creating clearer compliance pathways for medical AI companies worldwide.

For entrepreneurs considering entering the medical AI space, Bustami's advice is: "Be prepared for a long battle, find partners who truly understand the industry, and always put patient needs first."

Medical AI has never been an easy path, but it is precisely because of its high barriers to entry that companies who persevere build deeper moats and create greater societal value.